Condition: Arthritis, Rheumatoid · Sponsor: Centre Hospitalier Universitaire de Saint Etienne
Rheumatoid arthritis (RA) is the most common inflammatory joint disorder. Since twenty year and the use of synthetic disease-modifying anti-rheumatic drugs (csDMARDs) and biological (b)DMARD, remission can be reached. When remission is obtained, the physician has no recommendations for managing a step-down, and future guidelines will be useful to assist the clinician. Recent data suggest that tapering is feasible, but with high risk of flares. Flares are less frequent when bDMARD blood concentration is high. But, the optimal adalimumab concentration to keep before a step of tapering no targeting personal is unknown.
This description comes directly from the study's public registry record.
Hubert MAROTTE, MD PhD · (0)4 77 12 76 49 · hubert.marotte@chu-st-etienne.fr
Madjid AKROUR · (0)4 77 12 78 37 · madjid.akrour@chu-st-etienne.fr
Always discuss trial participation with your own doctor first.
| Infirmerie Protestante | Caluire-et-Cuire, France | Recruiting |
| Chd Vendee | La Roche-sur-Yon, France | Recruiting |
| Hopital Philibert | Lomme, France | Recruiting |
| Chu Montpellier | Montpellier, France | Recruiting |
| Ap-Hp Pitie Salpetriere | Paris, France | Recruiting |
| Chu Reims | Reims, France | Not Yet Recruiting |
| Chu Saint Etienne | Saint-Etienne, France | Recruiting |
| Chru Tours | Tours, France | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06528431